Botulinum toxin type a
As of the edition of 20 October 2026, Botulinum toxin type a is a protein: marketed, first approved in 2009 (JP); acts on SNAP25.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Protein
- Brand name
- Nuceiva
- First approved
- 21 January 2009 (JP)
- Approvals on record
- 12 in 2 regions
- Holder of the most recent approval
- GSK; 3 holders in all
- Registered trials
- 337, 29 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Botulinum toxin type a.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | P60880 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 79 | 49 | 10 | 4 |
| Phase 1 | 24 | 19 | 0 | 1 |
| Phase 2 | 77 | 62 | 1 | 7 |
| Phase 3 | 113 | 81 | 8 | 12 |
| Phase 4 | 44 | 30 | 2 | 5 |
| All trials | 337 |